Vincerx Pharma, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.26) Per Share (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Stock analysts at Leerink Partnrs increased their Q1 2024 earnings per share estimates for Vincerx Pharma in a research report issued on Sunday, March 31st. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.26) for the quarter, up from their previous forecast of ($0.40). The consensus estimate for Vincerx Pharma's current full-year earnings is ($0.85) per share. Leerink Partnrs also issued estimates for Vincerx Pharma's Q2 2024 earnings at ($0.27) EPS, Q3 2024 earnings at ($0.34) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.31) EPS and FY2025 earnings at ($1.11) EPS.

Separately, Cantor Fitzgerald restated an "overweight" rating on shares of Vincerx Pharma in a research report on Monday.

Vincerx Pharma Price Performance

Shares of Vincerx Pharma stock traded up $0.23 during trading on Wednesday, hitting $6.60. 417,486 shares of the company were exchanged, compared to its average volume of 1,075,495. The firm has a market capitalization of $141.31 million, a P/E ratio of -3.49 and a beta of 1.10. Vincerx Pharma has a 1-year low of $0.61 and a 1-year high of $9.37. The firm's fifty day moving average price is $3.97 and its 200 day moving average price is $1.99.

Hedge Funds Weigh In On Vincerx Pharma

Several institutional investors have recently modified their holdings of the business. Citadel Advisors LLC lifted its holdings in shares of Vincerx Pharma by 16.9% during the 4th quarter. Citadel Advisors LLC now owns 197,359 shares of the company's stock valued at $233,000 after purchasing an additional 28,530 shares in the last quarter. Sage Rhino Capital LLC lifted its holdings in shares of Vincerx Pharma by 1.0% during the 3rd quarter. Sage Rhino Capital LLC now owns 1,703,413 shares of the company's stock valued at $1,720,000 after purchasing an additional 16,476 shares in the last quarter. Walleye Capital LLC bought a new stake in Vincerx Pharma in the 2nd quarter valued at approximately $176,000. ExodusPoint Capital Management LP lifted its stake in Vincerx Pharma by 8.9% in the 2nd quarter. ExodusPoint Capital Management LP now owns 426,472 shares of the company's stock valued at $554,000 after acquiring an additional 34,724 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in Vincerx Pharma in the 1st quarter valued at approximately $28,000. Institutional investors own 44.02% of the company's stock.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.